Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: An open-label phase II multicentre trial (COVeRT study)

Anti-Cancer Drugs

Volumn 26, Issue 10, 2015, Pages 1083-1088

  Singhal, Nimit ^a   Mislang, Anna ^a   Karapetis, Christos S ^d   Stephens, Sonya ^a   Borg, Martin ^b   Woodman, Richard J ^d   Pittman, Kenneth ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

chemoradiation; cisplatin; non small cell lung cancer; oral vinorelbine

Indexed keywords

CISPLATIN; DEXAMETHASONE; NAVELBINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONSTIPATION; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG SAFETY; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIAL; FEMALE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; SURVIVAL; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 84944060083     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000291     Document Type: Article

References (19)

1. Australian Institute of Health and Welfare (AIHW). ACIM (Australian cancer incidence and mortality) books. Canberra: AIHW; 2012.
2. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2012. Cancer series no 74. Cat. No. CAN 70. Canberra: AIHW; 2012.
3. Okawara G, Mackay JA, Evans WK, Ung YC. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 2006; 1:377-393.
4. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:2181-2190.
5. Pignon JP, Stewart LA. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: a meta-analysis. Cancer 1996; 77:2413-2414.
6. Schaake-Koning C, Van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Effects of concomitant cisplatin and radiotherapy on inoperable NSCLC. N Engl J Med 1992; 326:524-530.
7. Bedano PM, Neubauer M, Ansari R, Govindan R, Einhorn LH, Bruetman D, et al. Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): an interim toxicity analysis of consolidation therapy. J Clin Oncol 2006; 24:374s.
8. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755-5760.
9. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002; 20:4191-4198.
10. De Lena M, Ramlau R, Hansen O, et al. Phase II trial of oral navelbine (NVB oral) in combination with cisplatin (P) followed by consolidation NVB oral single agent as consolidation therapy with oral vinorelbine in advanced nonsmall-cell lung cancer (NSCLC). Lung cancer 2005; 48:129-135.
11. Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: a randomized trial. Ann Oncol 1994; 5:37-42.
12. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001; 12:1643-1649.
13. Jassem J, Ramlau R, Karnicka-M?odkowska H, Krawczyk K, Krzakowski M, Zatloukal P, et al. A multicenter randomized phase II study of oral vs intravenous vinorelbine in advanced non-small cell lung cancer patients. Ann Oncol 2001; 12:1375-1381.
14. Jassem J, Kosmidis P, Ramlau R, et al. Oral vinorelbine (NVB oral) in combination with cisplatin (P): a novel active regimen in advanced non-small cell lung cancer (NSCLC). Ann Oncol 2003; 14:1634-1639.
15. Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage III non-small cell lung cancer. J Thorac Oncol 2008; 3:994-1002.
16. Descourt R, Vergnenegre A, Barlesi F, Lena H, Fournel P, Falchero L, et al. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study. J Thorac Oncol 2011; 6:351-357.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New Response Evaluation Criteria In Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
18. Huber RM, Engel-Riedel W, Kollmeier J, Andreas S, Staar S, Klautke G, et al. GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase III study. J Clin Oncol 2012; 30(15 Suppl):7001
19. Davis S, Yankelevitz D, Henschke C. Radiation effects on the lungs: clinical features, pathology, and imaging findings. Am J Roentgenol 1992; 159:1157-1164.